PL3020730T3 - Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych - Google Patents

Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych

Info

Publication number
PL3020730T3
PL3020730T3 PL15197139T PL15197139T PL3020730T3 PL 3020730 T3 PL3020730 T3 PL 3020730T3 PL 15197139 T PL15197139 T PL 15197139T PL 15197139 T PL15197139 T PL 15197139T PL 3020730 T3 PL3020730 T3 PL 3020730T3
Authority
PL
Poland
Prior art keywords
solid tumours
treating solid
il1rap antibodies
il1rap
antibodies
Prior art date
Application number
PL15197139T
Other languages
English (en)
Inventor
Thoas Fioretos
Marcus JÄRÅS
Original Assignee
Cantargia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45755402&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3020730(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantargia Ab filed Critical Cantargia Ab
Publication of PL3020730T3 publication Critical patent/PL3020730T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1033—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL15197139T 2011-01-19 2012-01-19 Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych PL3020730T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161434040P 2011-01-19 2011-01-19
PCT/GB2012/050120 WO2012098407A1 (en) 2011-01-19 2012-01-19 Anti - il1rap antibodies and their use for treating human
EP15197139.7A EP3020730B1 (en) 2011-01-19 2012-01-19 Anti-il1rap antibodies and their use for treating solid tumours
EP12705387.4A EP2665749B1 (en) 2011-01-19 2012-01-19 Anti-il1rap antibodies and their use for treating solid tumours

Publications (1)

Publication Number Publication Date
PL3020730T3 true PL3020730T3 (pl) 2019-06-28

Family

ID=45755402

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15197139T PL3020730T3 (pl) 2011-01-19 2012-01-19 Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych
PL12705387T PL2665749T3 (pl) 2011-01-19 2012-01-19 Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12705387T PL2665749T3 (pl) 2011-01-19 2012-01-19 Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych

Country Status (14)

Country Link
US (4) US9403906B2 (pl)
EP (3) EP3508498A1 (pl)
JP (1) JP5940093B2 (pl)
KR (1) KR101989134B1 (pl)
CN (2) CN103459424B (pl)
AU (1) AU2012208379B2 (pl)
BR (1) BR112013018399B1 (pl)
CA (1) CA2824719C (pl)
DK (2) DK2665749T3 (pl)
ES (2) ES2714716T3 (pl)
MX (1) MX354450B (pl)
PL (2) PL3020730T3 (pl)
RU (1) RU2597831C2 (pl)
WO (1) WO2012098407A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515497A (ja) 2008-03-26 2011-05-19 セレラント セラピューティクス インコーポレイテッド 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
EP3508498A1 (en) 2011-01-19 2019-07-10 Cantargia AB Novel agents and uses thereof
CA2828753C (en) 2011-03-16 2022-07-26 arGEN-X BV Antibodies to cd70
WO2013023015A2 (en) 2011-08-11 2013-02-14 Albert Einstein College Of Medicine Of Yeshiva University Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
CN106062002B (zh) 2013-12-17 2021-05-04 埃姆医疗有限公司 抵抗骨髓增生障碍或淋巴组织增生障碍的手段和方法
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) * 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US11137397B2 (en) 2014-11-24 2021-10-05 Albert Einstein College Of Medicine Peptides for blocking IL1RAP protein-protein interaction and uses thereof for treatment of disease
CA2990305A1 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
BR112018008908A2 (pt) * 2015-11-02 2018-11-27 Janssen Pharmaceutica Nv anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
EP3241845A1 (en) * 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US11359025B2 (en) * 2016-10-16 2022-06-14 Cantargia Ab Anti-IL1-RAP antibodies
CN110234661B (zh) 2016-12-01 2024-03-29 瑞泽恩制药公司 用于免疫pet成像的放射性标记的抗-pd-l1抗体
US10067409B2 (en) 2017-02-02 2018-09-04 James Harrison Elias Camera supporting base
EP3401332A1 (en) * 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
PL3625259T3 (pl) * 2017-05-16 2024-08-12 Byondis B.V. Przeciwciała anty-sirpalfa
USD951260S1 (en) 2017-05-19 2022-05-10 James Harrison Elias Electronic device mount
US11162632B2 (en) 2017-06-02 2021-11-02 James Harrison Elias Tripod stabilizing base
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
KR20200038490A (ko) * 2017-08-01 2020-04-13 시티 오브 호프 항-il1rap 항체
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
EP3837283B1 (en) 2018-08-16 2024-04-17 Cantargia AB Anti-il1rap antibody compositions
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
WO2020099653A1 (en) 2018-11-15 2020-05-22 Byondis B.V. HUMANIZED ANTI-SIRPα ANTIBODIES
USD900201S1 (en) 2018-11-29 2020-10-27 James Harrison Elias Tripod mount
USD888142S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD888815S1 (en) 2018-11-29 2020-06-30 James Harrison Elias Tripod mount
USD888140S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD888141S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD897414S1 (en) 2018-11-29 2020-09-29 James Harrison Elias Tripod mount
USD896878S1 (en) 2018-11-29 2020-09-22 James Harrison Elias Tripod mount
USD888139S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD888816S1 (en) 2018-11-30 2020-06-30 James Harrison Elias Tripod mount
USD896880S1 (en) 2018-11-30 2020-09-22 James Harrison Elias Tripod mount
USD888817S1 (en) 2018-11-30 2020-06-30 James Harrison Elias Tripod mount
USD896879S1 (en) 2018-11-30 2020-09-22 James Harrison Elias Tripod mount
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
US20220306750A1 (en) * 2019-08-12 2022-09-29 City Of Hope Il1rap antibodies
JP2023521174A (ja) * 2020-04-10 2023-05-23 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） インターロイキン１受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体
EP4211165A1 (en) 2020-09-14 2023-07-19 Ichnos Sciences SA Antibodies that bind to il1rap and uses thereof
JP2024500920A (ja) 2020-12-23 2024-01-10 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体
CN114736885A (zh) * 2022-05-27 2022-07-12 四川大学华西医院 一种携带bcr-abl1基因激酶区双位点突变的细胞株及其构建方法
AU2023345467A1 (en) 2022-09-21 2025-05-08 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use
AU2024270136A1 (en) 2023-05-05 2025-11-20 Otsuka Pharmaceutical Co., Ltd. Anti-il1rap antibodies
WO2025027529A1 (en) * 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
GB202402046D0 (en) * 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
WO2025201513A1 (zh) * 2024-03-29 2025-10-02 珠海丹序生物制药有限公司 抗il1rap抗体及其用途
WO2025209480A1 (zh) * 2024-04-02 2025-10-09 福佑泰生物制药公司 抗il1rap抗体以及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
CN1169754A (zh) * 1995-01-23 1998-01-07 霍夫曼-拉罗奇有限公司 人白介素-1受体辅助蛋白
PE64396A1 (es) * 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6280955B1 (en) 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
US20030215453A1 (en) 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
WO2002064630A2 (en) 2000-10-31 2002-08-22 Immunex Corporation Il-1 receptor accessory protein
PL374118A1 (pl) 2001-08-07 2005-10-03 Immunex Corporation Receptory interleukiny-1 w leczeniu chorób
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
JP2008529557A (ja) 2005-02-16 2008-08-07 ワイス 白血病の診断、予後診断および処置選択のための方法およびシステム
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
AU2006283532B2 (en) * 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US20090324618A1 (en) 2006-03-24 2009-12-31 Armstrong Scott A Novel signature self renewal gene expression programs
EP2076285A4 (en) 2006-10-19 2010-06-30 Merck Sharp & Dohme ANTIBODY ANTAGONISTS OF INTERLEUKIN 13 RECEPTOR 1
ES2796085T3 (es) 2008-01-15 2020-11-25 Univ Leland Stanford Junior Marcadores de células madre de leucemia mieloide aguda
JP2011515497A (ja) 2008-03-26 2011-05-19 セレラント セラピューティクス インコーポレイテッド 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
EP3508498A1 (en) 2011-01-19 2019-07-10 Cantargia AB Novel agents and uses thereof
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
CA2990305A1 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
BR112018008908A2 (pt) 2015-11-02 2018-11-27 Janssen Pharmaceutica Nv anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
WO2018071910A2 (en) 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies
US11359025B2 (en) 2016-10-16 2022-06-14 Cantargia Ab Anti-IL1-RAP antibodies

Also Published As

Publication number Publication date
CN103459424B (zh) 2017-11-10
AU2012208379B2 (en) 2017-04-20
US20210261674A1 (en) 2021-08-26
US9403906B2 (en) 2016-08-02
US20180334506A1 (en) 2018-11-22
DK3020730T3 (en) 2019-04-15
KR101989134B1 (ko) 2019-06-13
EP3508498A1 (en) 2019-07-10
MX354450B (es) 2018-03-05
RU2013138439A (ru) 2015-02-27
CN107929730A (zh) 2018-04-20
EP2665749B1 (en) 2016-01-13
JP5940093B2 (ja) 2016-06-29
RU2597831C2 (ru) 2016-09-20
ES2566538T3 (es) 2016-04-13
WO2012098407A1 (en) 2012-07-26
BR112013018399B1 (pt) 2022-11-01
KR20140003550A (ko) 2014-01-09
DK2665749T3 (en) 2016-03-21
EP3020730A1 (en) 2016-05-18
EP2665749A1 (en) 2013-11-27
CN103459424A (zh) 2013-12-18
US10005841B2 (en) 2018-06-26
US20140017167A1 (en) 2014-01-16
BR112013018399A2 (pt) 2017-08-01
US10995144B2 (en) 2021-05-04
US20170081414A1 (en) 2017-03-23
PL2665749T3 (pl) 2016-06-30
ES2714716T3 (es) 2019-05-29
CA2824719A1 (en) 2012-07-26
MX2013008375A (es) 2013-08-12
US11773174B2 (en) 2023-10-03
CA2824719C (en) 2020-06-02
EP3020730B1 (en) 2018-12-26
JP2014511348A (ja) 2014-05-15

Similar Documents

Publication Publication Date Title
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
PL3020730T3 (pl) Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych
IL288203A (en) Meditops and Meditop binding antibodies and their use
IL259436A (en) Antibodies against 3angptl and their uses
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL232399A0 (en) Anti-2fgfr antibodies and their use
IL227429A0 (en) The components and methods of cancer treatment
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
GB201111705D0 (en) Compounds and their use
IL229231A0 (en) Preparations and methods for the treatment of cancer
ZA201501558B (en) Means and method for treating solid tumours
ZA201504169B (en) Anti-adam28 antibody for treating cancer
GB201118482D0 (en) Treating tumours
SG10201601715YA (en) Novel Pharmaceutical Combinations And Methods For Treating Cancer
GB201116328D0 (en) Treatment for tumours
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
GB201104444D0 (en) Compounds and their use